Company Filing History:
Years Active: 2015-2016
Title: Innovations of Too-Hyon Cho in Cancer Treatment
Introduction
Too-Hyon Cho is a notable inventor based in Incheon, South Korea. He has made significant contributions to the field of biomedical research, particularly in the development of human monoclonal antibodies. With a total of 3 patents to his name, Cho's work focuses on innovative solutions for cancer treatment.
Latest Patents
One of Cho's latest patents is titled "Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof." This invention relates to human monoclonal antibodies that neutralize vascular endothelial growth factor receptors. Specifically, it involves human ScFv molecules that inhibit angiogenesis and provide compositions for cancer treatment. The disclosed monoclonal antibody demonstrates excellent neutralizing ability in living cells, surpassing that of commercially available antibodies. It effectively neutralizes vascular endothelial growth factor receptors in humans, mice, and rats, making it a promising candidate for anticancer studies.
Career Highlights
Too-Hyon Cho is currently associated with Pharmabcine Inc., where he continues to advance his research in monoclonal antibodies. His work has the potential to significantly impact cancer therapies and improve treatment outcomes for patients.
Collaborations
Cho has collaborated with notable colleagues, including Jin-San Yoo and Weon-Sup Lee, to further enhance the research and development of innovative therapeutic solutions.
Conclusion
Too-Hyon Cho's contributions to the field of cancer treatment through his innovative patents highlight the importance of research in developing effective therapies. His work exemplifies the potential of human monoclonal antibodies in combating cancer and improving patient care.